|Bid||46.910 x 800|
|Ask||46.980 x 1000|
|Day's Range||45.750 - 47.200|
|52 Week Range||12.200 - 47.640|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 6, 2018 - Aug 10, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||61.88|
Jim Cramer flies through his take on callers' favorite stocks in the lightning round, including a downtrodden pharmaceutical play.
SAN DIEGO, May 21, 2018 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (ARNA) today announced that data from a post-hoc analysis of the 22-week Phase 2 clinical study for its investigative drug candidate ralinepag, a next-generation, oral, selective and potent prostacyclin receptor agonist in development for the treatment of pulmonary arterial hypertension (PAH), will be presented at the American Thoracic Society (ATS) International Conference on May 23. Dr. Hap Farber, Professor of Medicine and Director, Pulmonary Hypertension Center, Boston University/Boston Medical Center, will present an analysis of the correlation between ralinepag plasma levels and improvements in functional and hemodynamic parameters in patients with pulmonary arterial hypertension (PAH). Arena previously announced topline Phase 2 results for ralinepag in PAH in which the primary efficacy analysis demonstrated a statistically significant absolute change from baseline in pulmonary vascular resistance compared to placebo. Ralinepag also demonstrated numerical improvement in 6-minute walk distance relative to placebo in patients on PAH specific background therapy.
NEW YORK, May 15, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Haemonetics ...
Momentum has slowed after the big move on Thursday but breadth is strong at around 4300 gainers to 2500 decliners, and the number of stocks at new 12-month highs is over 250. Overall it is still a positive day but the action is sloppy and there is risk of more profit taking into the close.
A live audio webcast of the presentations will be available under the investor relations section of Arena's website at www.arenapharm.com. Arena Pharmaceuticals is focused on delivering novel, transformational medicines with optimized pharmacology and pharmacokinetics to patients globally. Arena's proprietary pipeline includes multiple potentially first- or best-in-class programs with broad clinical utility.
The market is doing a nice job of being unpredictable with a sudden intraday spike on no obvious news. Strength in oil is receiving most of the credit for the overall market strength today but it is likely that there are some buy programs triggered now that the S&P500 has moved over the 50-day moving average at 2672 and has held. Bears were looking for the maket to stall out as it hit the top of the recent trading range that goes back to March 22, but they are now being squeezed as the market shrugs off the Iran news and doesn't seem to need any obvious positive news catalyst to keep on running.
Arena Pharmaceuticals (ARNA) reports wider-than-expected Q1 loss. Its three key pipeline candidates - ralinepag, etrasimod and Olorinab/APD371 - remain in focus.
- Achieved positive Phase 2 results for etrasimod in ulcerative colitis in March; Phase 3 preparations for ulcerative colitis and a development plan for Crohn's disease underway - Expect to initiate Phase ...
The pharma/biotech industry has witnessed a mixed first-quarter earnings picture so far. Let's see what's in store for some of the smaller players.
After eking out a modest gain in the week ended April 27, the iShares NASDAQ Biotechnology Index (ETF) (NASDAQ: IBB) pulled back this week amid some not-so-encouraging earnings reports and negative regulatory ...
NEW YORK, NY / ACCESSWIRE / May 3, 2018 / U.S. markets closed lower Wednesday after the Fed released a statement indicating an interest rate increase would be likely in the coming months. The Dow Jones ...
SAN DIEGO , May 2, 2018 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that the Company will release its first quarter 2018 financial results and provide a corporate update ...
Although Arena's (ARNA) only approved product, Belviq, puts up a dismal show so far, the company's efforts to improve the drug's performance might drive the stock in Q1.
- Arena's non-core, proprietary, preclinical compound provides strategic fit with Outpost Medicine's expertise in developing products for genitourinary disorders SAN DIEGO and INDIANAPOLIS , May 1, 2018 ...
NEW YORK, NY / ACCESSWIRE / April 18, 2018 / Markets continued to rise on Tuesday as investor focus continues to shift from geopolitical concerns to strong corporate earnings from major U.S. companies. ...
Arena Pharmaceuticals (ARNA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
SAN DIEGO, April 12, 2018 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (ARNA) today announced that data from a post-hoc analysis of the 22-week Phase 2 clinical study for its investigative drug candidate ralinepag, a next-generation, oral, selective and potent prostacyclin receptor agonist in development for the treatment of pulmonary arterial hypertension (PAH), will be presented at the International Society for Heart and Lung Transplantation (ISHLT) 2018 Annual Meeting on April 14. Dr. Raymond Benza, Cardiovascular Institute, Allegheny General Hospital, Pittsburgh, will present the results of an analysis assessing the impact of ralinepag treatment on mortality risk, as measured by three risk scoring methodologies (REVEAL, FPHN and COMPERA), in patients on PAH specific background therapy.
- Cardiology interventions and diagnostics are a big market, and the new field of remote monitoring, for arrhythmias and heart trouble, is a rapidly expanding component. Better remote monitoring technology ...
Arena Pharmaceuticals Inc’s (NASDAQ:ARNA) announced its latest earnings update in December 2017, which indicated that losses became smaller relative to the prrior year’s level – great news for investors Below,Read More...
SAN DIEGO, March 26, 2018 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (ARNA) today announced the completion of its previously announced underwritten public offering of 9,775,000 shares of its common stock at a price to the public of $41.50 per share, including 1,275,000 shares sold pursuant to the exercise in full of the underwriters' option to purchase additional shares. All of the shares were sold by Arena. Arena anticipates using the net proceeds from the offering for the clinical and preclinical development of drug candidates, including its planned Phase 3 programs for etrasimod for the treatment of ulcerative colitis and ralinepag for the treatment of pulmonary arterial hypertension, for general corporate purposes, including working capital and costs associated with manufacturing services, and for capital expenditures.